1. A method of protecting mammalian hepatocytes, said method comprising the step of bringing the mammalian hepatocytes into contact with an effective concentration of garcinol. The method of claim 1, wherein the effective concentration of garcinol is from about 0.78 μg / ml to about 6.25 μg / ml. A method for reducing elevated levels of cytokine expression in liver damage (hepatotoxicity) models in mammals, said method comprising the step of administering to said model mammal an effective amount of garcinol. 4. The method of claim 3, wherein the cytokine is a transforming growth factor G-1β (TGF-β1). The method according to claim 3, where the cytokine is a tumor necrosis factor-α.6. The method of claim 3, wherein the cytokine is interleukin-2 (IL-2). The method of claim 3, wherein the cytokine is interleukin-4 (IL-4). The method of claim 3, wherein the cytokine is interleukin-12 (IL-12). The method of claim 3, wherein the hepatotoxicity is caused by a toxin. The method of claim 3, wherein the hepatotoxicity is caused by drugs. The method of claim 3, wherein the hepatotoxicity is caused by ethanol. A method for reducing elevated levels of expression of an adhesive molecule in models of liver damage (hepatotoxicity) in mammals, said method comprising the step of administering to said model mammal an effective amount of garcinol. The method of claim 12, wherein the adhesive molecule is an intercellular adhesion molecule of 1 (ICAM-1 or CD 52). The method of claim 12, wherein the hepatotoxicity is caused by a toxin. The method of claim 12, wherein the hepatotoxicity is caused by drugs. A way to reduce elevated levels of liver and / or bile pi enzymes1. Способ защиты гепатоцитов млекопитающих, причем указанный способ включает стадию приведения гепатоцитов млекопитающих в контакт с эффективной концентрацией гарцинола.2. Способ по п.1, где эффективная концентрация гарцинола составляет от примерно 0,78 мкг/мл до примерно 6,25 мкг/мл.3. Способ снижения повышенных уровней экс
